Phase Forward signs agreement with Novo Nordisk for use of InForm for clinical trial data capture

7 May 2009

Phase Forward (NASDAQ: PFWD) has announced a multi-million dollar agreement that allows Danish company Novo Nordisk to use Phase Forward’s InForm electronic data capture (EDC) product across all clinical trial phases, from Phases I through IV.

Novo Nordisk is a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy.

Since signing an application service provider (ASP) arrangement in mid-2006, Novo Nordisk has successfully implemented and integrated global InForm studies with internal systems. Novo Nordisk is currently using InForm to support trials in more than 30 countries.

“We’ve had a very successful collaboration with Phase Forward over the last three years, and look forward to expanding the relationship,” said Henrik Lynge, Head of Clinical System Management in Novo Nordisk. “InForm’s ability to easily integrate with other in-house systems and the product’s scalability have been crucial to the implementation, enabling our team to streamline data collection for complex studies spanning multiple geographies.”

“Novo Nordisk is a global leader in diabetes care,” said Bob Weiler, chairman and CEO of Phase Forward. “We’re pleased to be supporting their efforts to constantly advance the treatment options for a disease that affects quality of life for millions of people worldwide.”

Bookmark this page

Your browser does not support inline frames or is currently configured not to display inline frames.	Your browser does not support inline frames or is currently configured not to display inline frames. Phase Forward signs agreement with Novo Nordisk for use of InForm for clinical trial data capture 7 May 2009 Phase Forward (NASDAQ: PFWD) has announced a multi-million dollar agreement that allows Danish company Novo Nordisk to use Phase Forward’s InForm electronic data capture (EDC) product across all clinical trial phases, from Phases I through IV. Novo Nordisk is a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Since signing an application service provider (ASP) arrangement in mid-2006, Novo Nordisk has successfully implemented and integrated global InForm studies with internal systems. Novo Nordisk is currently using InForm to support trials in more than 30 countries. “We’ve had a very successful collaboration with Phase Forward over the last three years, and look forward to expanding the relationship,” said Henrik Lynge, Head of Clinical System Management in Novo Nordisk. “InForm’s ability to easily integrate with other in-house systems and the product’s scalability have been crucial to the implementation, enabling our team to streamline data collection for complex studies spanning multiple geographies.” “Novo Nordisk is a global leader in diabetes care,” said Bob Weiler, chairman and CEO of Phase Forward. “We’re pleased to be supporting their efforts to constantly advance the treatment options for a disease that affects quality of life for millions of people worldwide.” Bookmark this page Your browser does not support inline frames or is currently configured not to display inline frames. To top	Your browser does not support inline frames or is currently configured not to display inline frames.